A Phase I Study of Irinotecan, Capecitabine (Xeloda), and Oxaliplatin in Patients With Advanced Colorectal Cancer.
| Author | |
|---|---|
| Abstract | :
The objective of the present phase I study was to define the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of irinotecan, capecitabine, and oxaliplatin given in combination (IXO regimen) to patients with previously untreated, unresectable advanced or metastatic colorectal cancer (CRC). |
| Year of Publication | :
2017
|
| Journal | :
Clinical colorectal cancer
|
| Date Published | :
2017
|
| ISSN Number | :
1533-0028
|
| URL | :
http://linkinghub.elsevier.com/retrieve/pii/S1533-0028(17)30132-9
|
| DOI | :
10.1016/j.clcc.2017.12.003
|
| Short Title | :
Clin Colorectal Cancer
|
| Download citation |